Table 2.

Time course of alterations of P450 content, activities of P450 isoforms, S9-GSTpi, S9-GST and mGST by Kupffer cell blockade

Group	Control	GdCl320-1 d	GdCl320-3 d	GdCl320-6 d
P-450 (nmol/mg·pro)	1.4 ± 0.4	0.87 ± 0.28b	0.90 ± 0.21b	0.59 ± 0.24b
NADPH-C (nmol/min·mg·pro)	14.5 ± 2.8	10.5 ± 1.8b	7.2 ± 1.0b	6.1 ± 0.8b
ANH (nmol/min·mg·pro)	0.038 ± 0.009	0.033 ± 0.006	0.024 ± 0.006b	0.024 ± 0.006b
AMD (nmol/min·mg·pro)	0.96 ± 0.07	0.82 ± 0.03a	1.31 ± 0.24b	1.31 ± 0.24b
EMD (nmol/min·mg·pro)	0.89 ± 0.06	0.74 ± 0.13a	1.53 ± 0.26b	2.5 ± 0.3b
S9-GSTpi (nmol/min·mg·pro)	1.07 ± 0.28	0.93 ± 0.17	1.1 ± 0.4	0.98 ± 0.23
S9-GST (nmol/min·mg·pro)	8.3 ± 0.91	0.2 ± 1.5a	11.4 ± 0.9b	11.1 ± 1.3b
mGST (nmol/min·mg·pro)	0.25 ± 0.03	0.28 ± 0.06	0.31 ± 0.04b	0.305 ± 0.015b

GdCl₃20-1 d, GdCl₃20-3 d, GdCl₃20-6 d: Mice were intraperitoneally injected with a signal dose of 20 mg/kg of GdCl_{3 ,} and sacrificed after 1 d, 3 d, and 6 d of GdCl₃ treatment. The hepatic microsome was prepared to assay the P450 content, and activities of P450 isoforms, S9-GSTpi, S9-GST and mGST (n = 8, mean ± SD,

^aP < 0.05,

^bP < 0.01 compared with control group).